$920,000.00 in Sales Expected for Heat Biologics Inc (NASDAQ:HTBX) This Quarter
Wall Street analysts expect Heat Biologics Inc (NASDAQ:HTBX) to announce sales of $920,000.00 for the current quarter, according to Zacks. Two analysts have made estimates for Heat Biologics’ earnings. The highest sales estimate is $1.10 million and the lowest is $740,000.00. Heat Biologics reported sales of $2.06 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 55.3%. The business is expected to announce its next quarterly earnings report on Thursday, March 26th.
On average, analysts expect that Heat Biologics will report full-year sales of $2.50 million for the current fiscal year, with estimates ranging from $2.10 million to $2.89 million. For the next fiscal year, analysts forecast that the company will report sales of $2.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Heat Biologics.
NASDAQ:HTBX remained flat at $$0.47 during mid-day trading on Thursday. The company had a trading volume of 80,231 shares, compared to its average volume of 403,018. Heat Biologics has a 52 week low of $0.35 and a 52 week high of $1.80. The firm has a market cap of $16.01 million, a price-to-earnings ratio of -0.52 and a beta of 1.80. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.29 and a quick ratio of 3.29. The firm’s 50-day moving average is $0.46 and its 200 day moving average is $0.59.
About Heat Biologics
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Recommended Story: How do buyers and sellers choose a strike price?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.